Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
survivin mRNA-transfected dendritic cells + hTERT mRNA-transfected dendritic cells + p53 mRNA-transfected dendritic cells
- Development stage
- Phase 1
- Lead developer
- Duke University
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
This autologous dendritic cell vaccine is a personalized cancer immunotherapy composed of dendritic cells transfected with messenger RNA (mRNA) encoding three distinct tumor-associated antigens: survivin, human telomerase reverse transcriptase (hTERT), and p53. Developed primarily at Duke University, the therapy involves harvesting a patient's monocytes via leukapheresis, differentiating them into mature dendritic cells, and using electroporation to introduce the mRNA transcripts. Once administered, these dendritic cells process the mRNA into proteins and present the resulting antigenic peptides on their surface via MHC class I and II molecules. This presentation primes and activates the patient's own CD8+ cytotoxic T lymphocytes and CD4+ helper T cells to recognize and eliminate tumor cells expressing these specific proteins. This multi-antigen approach is designed to overcome tumor heterogeneity and reduce the likelihood of immune escape. It has been primarily investigated in clinical trials for the treatment of malignant gliomas, specifically glioblastoma multiforme.
- Other names
- survivin/hTERT/p53 mRNA-transfected DC vaccinetri-antigen mRNA-pulsed dendritic cell vaccinesurvivin, hTERT and p53 mRNA-transfected dendritic cells
02
Targets
BIRC5 (Survivin)TP53 (Cellular Tumor Antigen p53 R175H)TERT (Telomerase)
Beyond the preview
Go deeper on survivin mRNA-transfected dendritic cells + hTERT mRNA-transfected dendritic cells + p53 mRNA-transfected dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on survivin mRNA-transfected dendritic cells + hTERT mRNA-transfected dendritic cells + p53 mRNA-transfected dendritic cells.